SLC5A2 and type 2 diabetes mellitus: Since some SLC transporters have been successfully developed as drug targets, for example dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2/SLC5A2) for the treatment of type 2 diabetes (Hanefeld and Forst, 2010), SLC transporters as a group are considered promising drug targets of great significance for drug discovery and development, only secondary to G protein coupled receptors (Lin et al, 2015).